Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320047 | 0.87 | RET (0.47) | GPR119KITCKS1BSKP1SKP2 | |
| SCHEMBL23086870 | 0.86 | GPR119 (0.51) | GPR119KITCKS1BSKP1SKP2 | |
| SCHEMBL22322252 | 0.86 | CKS1B (0.46) | GPR119KITCKS1BSKP1SKP2 | |
| SCHEMBL22322349 | 0.86 | MEN1 (0.54) | GPR119KITCKS1BSKP1SKP2 | |
| SCHEMBL31652129 | 0.86 | TLR9 (0.56) | TLR9GPR119TLR7ABCB1KIT | |
| SCHEMBL31651834 | 0.85 | TLR9 (0.48) | TLR9GPR119TLR7KITCKS1B | |
| SCHEMBL15599325 | 0.85 | TLR9 (0.50) | TLR9GPR119TLR7KITCKS1B | |
| SCHEMBL31651718 | 0.85 | TLR9 (0.50) | TLR9GPR119TLR7KITCKS1B | |
| SCHEMBL31652049 | 0.85 | TLR9 (0.50) | TLR9GPR119TLR7KITCKS1B | |
| SCHEMBL2421442 | 0.84 | MEN1 (0.47) | GPR119KITCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-3921319-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | disclosed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020160710-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | TLR9 3/4885GPR119 82/4885TLR7 1/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | TLR9 4/4885GPR119 180/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.